Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.00 USD
Change Today +0.08 / 0.50%
Volume 72.0K
OMER On Other Exchanges
Symbol
Exchange
Berlin
As of 10:43 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

201 Elliott Avenue West

Seattle, WA 98119

United States

Phone: 206-676-5000

Fax: 206-676-5005

ntract sales organization with 40 contract sales representatives solely dedicated to Omeros, all of whom are trained, in the field and calling on surgeons, hospitals and ambulatory surgery centers across the U.S. Outside of the U.S. and EU, the company is exploring potential regional partnerships to make Omidria available to ophthalmologists. Intellectual Property As of February 28, 2015, the company owned or held worldwide exclusive licenses to a total of 41 issued patents and 66 pending patent applications in the U.S. and 271 issued patents and 300 pending patent applications in foreign markets directed to therapeutic compositions and methods related to its development programs. The company’s patent portfolio for its PharmacoSurgery technology is directed to locally delivered compositions and treatment methods using agents selected from therapeutic classes. These patents and patent applications are directed to combinations of agents, generic and/or proprietary to the company or to others, delivered locally and intraoperatively to the site of any medical or surgical procedure. As of February 28, 2015, the company’s patent portfolio included 6 U.S. and 79 foreign issued or allowed patents, and 9 U.S. and 29 foreign pending patent applications, directed to its PharmacoSurgery products and development programs. The company’s issued PharmacoSurgery patents have terms that would expire as late as July 30, 2023 for Omidria, September 24, 2022 for OMS103, and July 16, 2029 for OMS201, and, if pending patent applications are issued, as late as December 1, 2035 for Omidria, August 3, 2032 for OMS103, and March 17, 2026 for OMS201. The company’s pending PharmacoSurgery patent applications are directed to combinations of agents, drawn from therapeutic classes, such as pain and inflammation inhibitory agents, spasm inhibitory agents, vasoconstrictive agents, mydriatic agents and agents that reduce intraocular pressure, that are used in ophthalmologic procedures, including intraocular procedures, arthroscopic procedures, and urologic procedures, including ureteroscopy, for Omidria, OMS103 and OMS201, respectively, as well as covering the specific combinations of agents included in each of these products and product candidates. Omidria-Ophthalmology: Omidria is encompassed by the company’s PharmacoSurgery patent portfolio. The relevant patents and patent applications in this portfolio are directed to combinations of agents, generic and/or proprietary to it or others, drawn from therapeutic classes, such as pain and inflammation inhibitory agents, mydriatic agents and agents that reduce intraocular pressure, delivered locally and intra-operatively to the site of ophthalmological procedures, including cataract and lens replacement surgery. As of February 28, 2015, the company owned 2 issued U.S. patents and 4 pending U.S. patent applications and 29 issued patents and 11 pending patent applications in foreign markets (Argentina, Australia, Canada, China, Europe, Hong Kong, Japan and International Patent Cooperation Treaty) that are directed to Omidria. OMS103-Arthroscopy: OMS103 is encompassed by the company’s PharmacoSurgery patent portfolio. The relevant patents and patent applications in this portfolio are directed to combinations of agents, generic and/or proprietary to it or others, drawn from therapeutic classes, such as pain and inflammation inhibitory agents and vasoconstrictive agents, delivered locally and intra-operatively to the site of medical or surgical procedures, including arthroscopy. As of February 28, 2015, the company owned 2 issued U.S. patents, 3 pending U.S. patent applications, and 42 issued patents and 16 pending patent applications in foreign markets that are directed to OMS103. OMS201-Urology: OMS201 is encompassed by the company’s PharmacoSurgery patent portfolio. The relevant patents and patent applications in this portfolio are directed to combinations of agents, generic and/or proprietary to the company or others, drawn from therapeutic classes, such as pain and inflammation inhibitory agents and spasm inhibitory agents, delivered locally and intra-operatively to the site of medical or surgical proc

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMER:US $16.00 USD +0.08

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMER.
View Industry Companies
 

Industry Analysis

OMER

Industry Average

Valuation OMER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 710.3x
Price/Book 27.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 612.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit www.omeros.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.